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GLOSSARY: 
 
Human microbiota ± the collection of microbes living in and on the human body 
Human microbiome ± the collective genomic content of the human microbiota 
Resistome ± the complement of all antibiotic resistance genes encoded by a 
microbial community 
Metagenomic functional selection ± a culture-independent method for capture of 
selectable functions from microbial metagenomic DNA through heterologous 
expression in an indicator host strain. 
 
 
SUMMARY: 
 
Since the discovery and clinical application of antibiotics, pathogens and the 
human microbiota have faced a near continuous exposure to these selective 
agents. A well-established consequence of this exposure is the evolution of 
multidrug-resistant pathogens which can become virtually untreatable. Less 
appreciated are the concomitant changes in the human microbiome in response 
to these assaults and their contribution to clinical resistance problems. Studies 
have shown that pervasive changes to the human microbiota result from 
antibiotic treatment and that resistant strains can persist for years. Additionally, 
culture independent functional characterization of the resistance genes from the 
microbiome has demonstrated a close evolutionary relationship between 
resistance genes in the microbiome and in pathogens. Application of these 
techniques and novel cultivation methods are expected to significantly expand 
our understanding of the interplay between antibiotics and the microbiome. 
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Click here to view linked References
INTRODUCTION: 
 
Antibiotic compounds work to either stop bacteria from growing (bacteriostatic 
agents) or to kill them outright (bacteriocidal agents). The effectiveness of these 
FRPSRXQGV³DJDLQVWOLIH´VWHPVIURPWKHLUDELOLW\WREORFNFULWLFDOEDFWHULDOFHOOXODU
processes [1,2]. Since these cellular targets are often highly genetically and 
structurally conserved across diverse members of the bacterial kingdom, 
deployment of an antibiotic compound against a specific bacterium (e.g. a 
pathogen) is quite likely to impart collateral damage to the bacterial community 
which shares the environment of the intended target organism. The spectrum of 
unintended effects of antibiotic therapy is likely to be considerably larger than 
simple growth inhibition of susceptible strains, especially considering the role of 
these bioactive organic compounds as multi-activity signaling molecules [3]. 
Almost every surface of the human body after birth is colonized by a rich and 
diverse community of commensal microbes [4-6], and this microbiota has 
substantial and continuous effects on human health and physiological 
development, including dietary and nutritional processing, prevention of pathogen 
invasion, and immune system maturation [7-9]. Accordingly, antibiotic treatment 
to prevent or eradicate a pathogenic infection at virtually any body site is likely to 
produce both short-term and long-term impacts on the commensal microbiota 
and its encoded microbiome [10]. These effects can be broadly categorized into 
two interrelated categories(Figure 1): (1) ones which change the relative 
proportions of different species in the microbiota, with introduction of a new 
species or complete eradication of an existing species as extreme scenarios [11-
16], and (2) ones which alter the antibiotic resistome encoded by members of the 
microbiota [17,18]. In the first case, changes in the architecture of the microbiota 
can dramatically perturb the carefully evolved homeostasis of microbiota-host 
mutualism, which can lead to both transient and persistent changes in host 
physiology and health [19,20]. In the latter case, enrichment and exchange of 
resistance genes within the microbiota increase the accessibility of these 
elements to potentially pathogenic organisms, challenging our ability to treat their 
subsequent infections [21,22].  
 
 
  
MAIN TEXT: 
 
Antibiotic induced changes in microbial community structure 
 
Dramatic advances over the past few years in next-generation DNA sequencing 
technology have enabled a series of recent high-resolution molecular 
characterizations of the change in microbiota architecture in humans and model 
organisms in response to antibiotic treatment. Deep 16S rDNA pyrosequencing 
was used to investigate the effect of two courses of ciprofloxacin on the 
gastrointestinal microbiota of three healthy individuals, which revealed dramatic 
and immediate antibiotic-induced decreases in phylogenetic diversity of the 
previously stable microbial ecosystem [12,15]. While the microbiota began to 
recover to a relatively stable state within a week after antibiotic insult, the pre-
treatment architecture had not fully recovered within 6-10 months, including the 
apparent complete loss of low-abundance members of the community. Similarly, 
a combination of 16S sequencing and terminal-restriction fragment length 
polymorphism (T-RFLP) was used to measure the short- and long-term effects of 
clarithromycin and metronidazole, which are standard treatment for Helicobacter 
pylori eradication, on the throat and gastrointestinal microbiota of three treated 
human subjects compared to three controls [16]. Like the ciprofloxacin study, the 
combination antibiotic treatment caused transient decreases in microbiota 
diversity in both the throat and the gut, and the overall community architecture 
had only partially recovered one and four years after treatment. Interestingly, the 
throat microbiota was found to be more stable after antibiotic treatment and over 
long periods than the intestinal microbiota.  
 
One of the challenges in fully understanding the mechanisms of antibiotic-
induced microbiota perturbations is the inherent baseline variability of the 
microbiota of different human individuals, which is confounded by the small 
sample size employed in human studies to date. One approach to address this 
variation is to use animal models, where host genotype, diet and other variables, 
which may impact baseline microbiota composition can be controlled, while still 
employing modern high-resolution molecular methods to characterize the 
microbiota [13,14]. A major finding of such studies is that different antibiotic 
regimens cause reproducible distinct short-term and long-term impacts on the 
microbiota in murine models. Mice treated with a combination of amoxicillin, 
metronidazole and bismuth had significant changes in abundance and structure 
of their cecal microbiota following treatment, but there was also significant rapid 
recovery of the community structure towards baseline after removal of the 
treatment. In contrast, treatment with the broad-spectrum antibiotic cefoperazone 
caused persistent depression in overall community diversity up to six weeks after 
WUHDWPHQWZLWKGUDZDOWKRXJKFRPPXQLW\FRPSRVLWLRQZDVµQRUPDOL]HG¶ZKHQWKH
treated cohort was co-housed with a non-treated animal, presumably via 
coprophagy [14]. In another experiment, mice treated with the glycopeptide 
vancomycin, which exclusively targets gram-positive organisms, showed similar 
effects to the combination treatment, where the antibiotic-induced community 
perturbations recovered after removal of treatment but differed from both the 
previous treatments in that vancomycin did not result in a major decrease in 
overall bacterial biomass [13]. Of note, all treatments caused transient increases 
in the normally low-abundance Proteobacteria at the expense of the normally 
dominant Firmicutes and Bacteroidetes, which is particularly intriguing given the 
recent rapid global proliferation of extensively drug resistant strains of 
Protoeobacterial human pathogens, including Klebsiella pneumoniae, 
Acinetobacter baumanii, Pseudomonas aeruginosa, and extended-spectrum 
beta-lactamase producing Enterobacteriaceae [23]. 
 
The simplest mechanistic explanation for short-term antibiotic-induced changes 
in the microbiota is differences in the activity spectrum of the drug; drug resistant 
or insensitive bacteria proportionally increase at the expense of susceptible ones. 
For instance, the relative enrichment of the Proteobacteria and Tenericutes in 
mice cecal microbiota in response to Vancomycin is rationalized by innate 
resistance to this drug by these groups [13]. Vancomycin targets a peptidoglycan 
precursor needed for normal cell-wall synthesis, but is ineffective against these 
bacteria due to its inability to penetrate the Proteobacterial outer membrane, and 
the lack of a cell wall in Tenericutes comprised of peptidoglycan. However, 
antibiotics can also perturb the complex architecture of the microbiota through 
indirect or multilayered effects; for example, bacteria which are insensitive to 
direct action of an antibiotic might nevertheless still be affected if other bacteria 
or environmental factors which they are dependent on are changed by antibiotic 
treatment [19]. For instance, mice treated with the broad-spectrum combination 
metronidazole, neomycin and vancomycin significantly down-regulated intestinal 
expression of RegIIIJ, a secreted C-type lectin which is induced by commensal 
microbes and kills gram-negative bacteria [20]. This down-regulation of the host 
innate immune defense in turn significantly decreased in vivo killing of 
vancomycin-resistant enterococci, demonstrating the indirect effects of antibiotic 
treatment on a pathogenic microbe. 
 
 
Persistent effects on the antibiotic resistome following antibiotic treatment 
 
A major expectation from repeated antibiotic exposure of the microbiota is an 
increasing abundance of antibiotic resistance determinants, caused by the 
growth advantage of resistant organisms during antibiotic treatment and further 
exacerbated through the lateral exchange of resistance determinants between 
diverse bacteria. Growth of this resistant population and their associated 
resistance genes is obviously dependent on the existence of a basal level of 
resistance in the microbiota; however, even in absence of direct anthropogenic 
treatment with antibiotics such populations are generally found present in human, 
animal and even µSULVWLQH¶ environmental microbiota [24].  Studies using 
anaerobic and aerobic cultivation methods have shown that the oral microbiota of 
children that have not received antibiotics contain a subpopulation of different 
species that are resistant to tetracycline and other antibiotics [25]. Aerobic 
cultivation of enterobacteria from the gut of human volunteers free of antibiotics 
for over one year documented mean levels of resistance in excess of 20% to 13 
different antibiotics [17]. Antibiotic treatment is expected to selectively increase 
the abundance of these organisms, leading to increased prevalence of their 
resistance genes and hence increasing the likelihood of their dissemination via 
lateral gene transfer. Indeed, a cultivation-based study documented significant 
increases in amoxicillin resistance levels in children exposed to this antibiotic in 
the three months after exposure, compared to a non-exposed control group [26].  
 
It has long been hypothesized that resistance elements confer a fitness 
disadvantage to the host, and hence resistant strains should be outcompeted by 
susceptible counterparts once antibiotic pressure is removed [27]. Unfortunately, 
there is a growing appreciation that antibiotic resistance can persist for long 
periods in absence of treatment, as highlighted by the basal levels of resistance 
in the microbiota described above. Cultivation based studies have shown that 
treatment with clarithromycin leads to high level resistance within intestinal 
Enterococcus sp. during treatment and that the highly resistant Enteroccocus sp. 
persisted in several patients for 1-3 years after treatment ended [28]. Similar 
results have been obtained for Staphyllococcus epidermis isolated from the 
nostrils of antibiotic treated patients [29] and Bacteriodes sp. isolated from the 
gut [30]. Furthermore, a culture independent PCR assay showed that the 
abundance of specific macrolide resistance genes had increased up to 10,000 
fold compared to pre-treatment levels, and persisted up to two years after 
cessation of antibiotic treatment [31]. 
 
Mechanisms underlying the persistence of antibiotic resistance are complex and 
include compensatory adaptations and co-selection [32-35]. An elegant 
demonstration of how compensatory mutations lead to a reduced fitness cost 
associated with antibiotic resistance gene carriage was shown for two lineages of 
Bacteroides thetaiotaomicron from the human gut microbiota [36]. In individuals 
exposed to clindamycin over seven days, a dominant clone of B. 
thetaiotaomicron acquired the ermG or F resistance gene, initially leading to a 
fitness cost in absence of antibiotic selection. However, resistant clones from this 
lineage isolated two weeks later had significantly reduced fitness cost associated 
with the carriage of this resistance gene, highlighting the rapid adaptations that 
can occur in vivo [36]. Interestingly studies on the persistence of antibiotic 
resistance after cessation of antibiotic therapy in livestock microbiota document 
more drastic reductions in the prevalence of antibiotic resistance compared to 
those shown in the human microbiota [37]. The larger reductions in antibiotic 
resistance levels in livestock microbiota may result from the turnover of the 
sampled individuals; yet even under these conditions of rapid turnover, antibiotic 
resistance genes are expected to persist in life stock microbiota for decades after 
abolishment of antibiotic use [32].  
 
 
Transfer of antibiotic resistance determinants  
 
The dissemination of antibiotic resistance genes necessitates the physical 
transfer or acquisition of the genetic element encoding antibiotic resistance. The 
mechanisms responsible for this transfer are conjugation, transformation or 
transduction, all of which are fully capable of transferring antibiotic resistance 
determinants in vitro from resistant donor organisms to susceptible recipient 
organisms [21,38]. Such transfer events have been documented for strains 
isolated from virtually any reservoir in vitro under laboratory conditions. More 
complex in vitro systems mimicking the biofilm community structure of the oral 
microbiota have also been used to demonstrate transfer of antibiotic resistance 
genes between distant genera through both conjugation as well as 
transformation [39]. In vitro fermentation systems simulating the human intestinal 
system have also been used for the investigation of the horizontal transfer of 
extended spectrum beta-lactamases. While transfer of resistance genes was 
accelerated greatly by the administration of cefotaxime to which the donor strain 
harbored resistance, a base line of transconjugants were present shortly after 
introduction of the resistant donor strain even in absence of antibiotic selection 
[40].  
 
To extend these in vitro findings, a number of groups have studied the in vivo 
transfer of antibiotic resistance genes in animal models. Germ free mice 
colonized with enterococcal donor and recipient strains were used to 
demonstrate the conjugal transfer of vancomycin resistance with appreciable 
rates and resulting in a stable population of transconjugants [41]. However, 
transfer occurred at much lower rates in mice colonized with the complex 
microbiota from feces recovered from healthy human subjects. Indeed transfer 
events were only documented between strains of the same species and these 
transconjugants did not stably colonize the microbiota [41]. The strong 
preferential transfer of vancomycin resistance to closely related strains was also 
recently confirmed for a larger array of clinical gram positive isolates in vitro [42]. 
Recently, transfer of the extended spectrum beta lactamase CTX-M-9 was 
shown in rats colonized with human microbiota between strains of Salmonella 
enterica and Escherichia coli; however, the transconjugants were again only 
transiently present in the rat microbiome and only during treatment with selective 
antibiotics [43].  
 
Notably, a series of experiments have directly investigated the transfer of 
antibiotic resistance genes within the gut microbiota of healthy human subjects. 
In one study healthy human volunteers ingested cultures of Enterococcus 
faecium resistant to either glycopeptide or streptogramin antibiotics. Fecal 
samples from the individuals were sampled using cultivation-based methods and 
enterococcal isolates resistant to virginiamycin or vancomycin were enumerated. 
It was found that the ingested resistant strains were able to multiply and persist in 
the human gut environment for 7 days; however, no transfer events were 
detected as all resistant isolates were identical to the ingested strains based on 
the pulsed field gel electrophoresis pattern [22]. These experiments were 
followed up with a study demonstrating the in vivo transfer of the vanA resistance 
determinant from a donor Enterococcus faecium strain of animal origin to a 
recipient Enterococcus faecium strain of human origin in the intestine of healthy 
human subjects [44]. Similar results were shown for the sulfonamide resistance 
gene sul2 within strains of E. coli in the human intestine [45]. 
 
The in vivo studies on antibiotic resistance transfer highlight the importance not 
only of the transfer event but also the subsequent ability of the strain to establish 
within the microbiota. While there is a growing body of research documenting 
persistent effects on the microbiome community structure and the resistance 
levels within the microbiota, there is limited support yet for this from controlled in 
vivo studies in both animal and human microbiota. This apparent discrepancy 
may result from the somewhat artificial conditions of controlled in vivo studies 
where donor and recipient strains from a different microbiota are introduced to an 
already established microbiota. The stability of the established microbiota and 
the foreign origin of donor and recipient strains may be an important factor 
explaining the contrasting results. Another consequence of focusing the attention 
on predefined donor and recipient strains in controlled in vivo experiments so far 
is that the dissemination of antibiotic resistance genes within the total microbial 
community is not quantified. 
 
 
Microbiome wide characterization of the antibiotic resistome 
 
Previous culture based studies have thus clearly established that the human 
commensal microbiota harbors many multidrug resistant isolates, whose load of 
antibiotic resistance genes have increased steadily over the past decades. 
However, the majority of constituents in the microbiota have remained 
inaccessible to traditional culturing techniques, and molecular methods have 
estimated the gastrointestinal tract is home to nearly 1000 different species and 
over 7000 different strains [4,10], indicating our picture of the antibiotic resistome 
of the human microbiota from culturing-studies is incomplete. In collaboration 
with Gordon and colleagues, we (Dantas) recently demonstrated that use of strict 
anaerobic conditions and a specially formulated rich gut microbiota medium 
enabled culturing of over 70% of genus level OTUs observed in corresponding 
XQFXOWXUHG³FRPSOHWH´PLFURELRWD[46]. While this is undoubtedly a dramatic 
LPSURYHPHQWRYHUSDVWHVWLPDWHVRIPLFURELRWD³FXOWXUDELOLW\´WKHQHHGIRU
culture-independent methods for complete characterization of the resistome 
remains acute. 
 
The most commonly used culture-independent method for detection and 
quantification of antibiotic resistance genes in polymicrobial samples is PCR with 
primers homologous to known resistance gene sequences [47] (Fig 2B). For 
example, quantitative PCR (qPCR) screens were recently used to quantify the 
levels of tet and erm genes, conferring resistance to tetracycline and macrolide, 
lincosamide, and streptogramin B antibiotics respectively, in animal and human 
waste water [48], highlighting potential routes of dissemination of resistance 
genes between human, animal and environmental microbiota. However, the 
extraordinary specificity of PCR based studies is also an important limitation of 
the technique: because PCR can only be used to interrogate a sample for known 
genes, it is an ineffective method for identifying novel resistance genes. 
 
A complementary culture-independent method which enables characterization of 
ERWKNQRZQDQGQRYHOUHVLVWDQFHJHQHVLVWHUPHGµPHWDJHQRPLFIXQFWLRQDO
VHOHFWLRQ¶Fig 2B), wherein total community microbial (metagenomic) DNA is 
extracted from any arbitrary source (e.g. a fecal microbiota sample) and cloned 
into an antibiotic susceptible indicator strain (e.g. E. coli) [17,47]. Indicator strains 
transformed with DNA that encode resistance genes can be functionally selected 
by plating the recombinant library on antibiotic media. Functionally selected 
metagenomic DNA inserts are amplified and sequenced to identify the captured 
resistance genes. We use the phrase metagenomic functional selections to 
specifically refer to the idea of subjecting metagenomic DNA to an experimental 
functional assay, generally through shot-gun expression in a heterologous host 
[49], in an attempt to distinguish this approach from broader definitions of 
"functional metagenomics", which include sophisticated computational 
approaches for annotation of functions in shot-gun metagenomic sequence data, 
but without direct experimental validation [50]. As with PCR-based screens, 
metagenomic functional selections were first developed and applied for 
resistome characterization of environmental microbial communities [24,47], and 
have subsequently been successfully applied to identify a variety of enzymatic 
functions from cultured and uncultured microbes, including genes and pathways 
for degradation of or resistance towards numerous xenobiotics [51,52]. 
 
We have used metagenomic functional selections to demonstrate that the 
resistome of the human gut microbiota had been profoundly under-sampled 
using traditional culture-based methods [17,49]. We identified several hundred 
antibiotic resistance genes within the microbial communities of two healthy, 
unrelated adults. Over 95 % of the resistance genes in cultured Proteobacterial 
isolates from these microbiota were highly similar to previously characterized 
genes (>90 % nucleotide identity), many of which had been identified in 
pathogens. In sharp contrast, application of the same method to directly 
interrogate uncultured microbiota from the same fecal samples yielded 
predominantly novel resistance genes, with low sequence identity to previously 
characterized genes (<61 % nucleotide identity). Furthermore, while over 65 % of 
the resistance genes derived from cultured isolates were highly similar between 
the two individuals, <10 % of the resistance genes from culture-independent 
sampling were similar between these two individuals. Our results exposed the 
substantial under-sampling of resistance genes in prior studies of human 
microbiota, which stemmed from a reliance on culture-dependent methods. 
Importantly, our data underscore the utility of metagenomic functional selections 
for resistance gene discovery and obtaining a culture-unbiased depiction of the 
diverse and personalized resistomes of the microbiota in humans.  
 
With Gordon and co-workers, we (Dantas) recently showed that inter-individual 
differences in human microbiota antibiotic resistomes could be detected by 
VXEMHFWLQJERWKXQFXOWXUHGµFRPSOHWH¶IHFDOPLFURELRWDDVZHOODVSRROVRI
phylogenetically-representative fecal culture collections to metagenomic 
functional selections [46]. Notably, the metagenomic detection of specific 
resistance genes (e.g. encoding amikacin resistance) in complete samples 
significantly correlated with the fraction of sample-matched cultured isolates 
phenotypically resistant to those compounds, and the exact genes were then 
reconfirmed to be present in those cultured isolates by PCR. Additionally, when 
transplanted into gnotobiotic mice, complete and cultured communities exhibited 
similar colonization dynamics, biogeographical distribution, and responses to 
dietary perturbations, and these personalized culture collections could be 
enriched in vivo for taxa suited to specific perturbations. These methods for 
careful recapitulation and manipulation of microbiota both in vitro and in vivo hold 
great promise for quantifying the phylogenetic specificity of specific resistance 
genes and interrogating correlations between prevalence and dynamics of 
antibiotic resistomes and specific genetic and environmental variables. 
 
 
CONCLUSION:  
 
Antibiotic treatment leads to pervasive changes in the microbial community 
structure and persistent increases in antibiotic resistance amongst sampled 
cultivatable species. This results from the rapid proliferation of antibiotic resistant 
strains present in low basal levels in the microbiota and through horizontal 
transfer of antibiotic resistance genes. While advances in sequencing technology 
have driven increases in our knowledge of the effects of antibiotic treatment on 
total community architecture, we still have a limited understanding of the 
evolutionary pathways through which the genetic elements encoding antibiotic 
resistance spreads within a community. However, the application of 
metagenomic functional selections, novel cultivation methods and high 
throughput sequencing on microbiota exposed to antibiotics should enable a 
more detailed understanding of the processes governing the interplay between 
antibiotics and the resistant microbiome and its contribution to clinical problems 
with antibiotic resistance.  
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FIGURE LEGENDS 
 
Figure 1: The effects of antibiotic treatment on the microbiota. (A) Prior to 
antibiotic selection the constituents of the microbiota range in sensitivities 
towards antibiotics from sensitive (blue, green and yellow) to resistant (red). 
During exposure susceptible organisms will decrease in abundance, unless they 
acquire resistance determinants from viable resistant organisms. Upon cessation 
of treatment some of the susceptible organisms may increase in abundance to 
previous levels, whereas others will be lost from the microbiota. (B) During 
antibiotic exposure the microbial community architecture is significantly altered 
due to the differing sensitivities of the constituent microbes. Following cessation 
of antibiotic treatment community architecture largely re-establishes yet certain 
changes persist. (C) Schematic depiction of the changes in species diversity and 
antibiotic resistance levels upon antibiotic treatment followed by partial recovery 
of microbial community structure and resistance levels upon cessation of 
treatment.  
 
Figure 2: Schematic representation of methods for characterizing antibiotic 
resistance from human fecal microbiota. (A) The traditional method for 
characterizing antibiotic resistant isolates from the fecal microbiota begins with 
phenotypic growth assays of individual cultured clones on antibiotic-containing 
media to determine the minimum inhibitory concentration (MIC). Resistance 
genes are detected by either PCR amplification based on the sequence of known 
genes or by whole genome sequencing followed by computational annotation of 
resistance genes using homology to known genes. (B) Culture-independent 
resistome approaches enable microbiota-wide characterization of resistance 
genes. Detection and quantification of known resistance genes can be 
accomplished by PCR. Characterization of both known and novel resistance 
genes can be accomplished through metagenomic functional selections, wherein 
metagenomic DNA is directly extracted from the fecal sample and cloned into an 
expression system in a cultivable, genetically-tractable host strain (e.g. E. coli). 
Metagenomic transformants harboring DNA fragments that encode antibiotic 
resistance genes are selected by subjecting the library of clones to specific 
antibiotics at concentrations which inhibit the growth of the untransformed 
indicator strain. Selected DNA fragments can then be sequenced to identify the 
specific resistance genes. 
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Highlights:  
1) Evolution of antibiotic resistance in pathogens has become a global public 
health threat  
2) Microbiome wide characterization of resistance genes supports recent genetic 
exchange between the resistant microbiota and pathogens  
3) Treatment with antibiotics leads to pervasive changes in the composition of 
the human microbiota and its encoded resistome 
4) In vivo studies have demonstrated transfer of antibiotic resistance genes 
within the microbiota even in absence of exposure 
5) Enrichment of resistance genes in the microbiota is likely to exacerbate 
problems with pathogenic resistance  
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